Tevogen TVGN
NASDAQ TVGN
$7.29 -0.05 (-0.68%)
At close: Sep 10, 2026 · 4:00 PM EDT

Tevogen (TVGN) Non-Current Debt (2024 - 2026)

Tevogen's (TVGN) quarterly Non-Current Debt came in at $6.4 million in Q2 2026, up 45.45% on a YoY basis from $4.4 million in Q2 2025, and little changed quarter-over-quarter from $6.4 million in Q1 2026.

Analysis

Tevogen (TVGN) Non-Current Debt (2024 - 2026) Analysis & Trends

Tevogen (TVGN) has reported Non-Current Debt for 3 consecutive years, with $6.4 million the latest figure, recorded in Q2 2026.

  • For the quarter ending Q2 2026, Non-Current Debt rose 45.45% year-over-year to $6.4 million; the trailing twelve-month figure through Jun 2026 stood at $6.4 million (up 45.45% YoY), and the FY2025 full-year result was $4.4 million, up 340.0% from the prior year.
  • Non-Current Debt was little changed at $6.4 million in Q2 2026 per TVGN's latest filing, from $6.4 million in the prior quarter.
  • Across five years, Non-Current Debt topped out at $6.4 million in Q1 2026 and bottomed at $1.0 million in Q4 2024.
  • Historically, Non-Current Debt has averaged $4.3 million across 3 years, with a median of $4.4 million in 2025.
  • The sharpest annual moves came in 2025 and 2026: Non-Current Debt soared 340.0% in 2025, then surged 45.45% in 2026.
  • Over 3 years, Non-Current Debt stood at $1.0 million in 2024, then surged by 340.0% to $4.4 million in 2025, then soared by 45.45% to $6.4 million in 2026.
  • According to Business Quant data, Non-Current Debt over the past three periods registered $6.4 million, $6.4 million, and $4.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Debt (Qtr)
1 Krystal Biotech 10.21 Bn 9.37 Bn 112.79 Mn -
2 CRISPR Therapeutics AG 5.04 Bn 5.04 Bn - 586.20 Mn
3 Iovance Biotherapeutics 3.65 Bn 3.36 Bn 55.72 Mn -
4 Legend Biotech 3.54 Bn 2.57 Bn 251.50 Mn -
5 uniQure 2.95 Bn 2.95 Bn 5.49 Mn 50.15 Mn
6 Beam Therapeutics 2.55 Bn 2.55 Bn - 100.26 Mn
7 Precigen 2.39 Bn 2.39 Bn 52.17 Mn 93.88 Mn
8 Sarepta Therapeutics 2.16 Bn 1.37 Bn 251.87 Mn 847.62 Mn
9 Vericel 1.93 Bn 1.77 Bn 56.40 Mn -
10 Tevogen 27.76 Mn 27.76 Mn - 6.40 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 6.40 Mn
Mar 31, 2026 6.40 Mn
Dec 31, 2025 4.40 Mn
Sep 30, 2025 4.40 Mn
Jun 30, 2025 4.40 Mn
Mar 31, 2025 3.00 Mn
Dec 31, 2024 1.00 Mn